We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Edited by
Allan Young, Institute of Psychiatry, King's College London,Marsal Sanches, Baylor College of Medicine, Texas,Jair C. Soares, McGovern Medical School, The University of Texas,Mario Juruena, King's College London
Mood disorders are causes of significant morbidity and mortality and can have their origins in early life and can affect youth development. In this chapter, we describe the significance of depression in children and adolescents, as well as potential management strategies for mood disorders in youth. We describe the establishment of viable treatment plans (including the stages of diagnostic assessment, selection of treatments, and evaluation of treatment response) in collaboration with the patient and their family, as well as the school, and describe how psychopharmacological or psychotherapeutic interventions may be used across unipolar depression and bipolar disorder. We also discuss potential treatment adaptations for pediatric populations, potential adverse effects for children and adolescents, comorbidities, and ways to manage treatment resistance.
Universal depression screening in youth typically focuses on strategies for identifying current distress and impairment. However, these protocols also play a critical role in primary prevention initiatives that depend on correctly estimating future depression risk. Thus, the present study aimed to identify the best screening approach for predicting depression onset in youth.
Methods
Two multi-wave longitudinal studies (N = 591, AgeM = 11.74; N = 348, AgeM = 12.56) were used as the ‘test’ and ‘validation’ datasets among youth who did not present with a history of clinical depression. Youth and caregivers completed inventories for depressive symptoms, adversity exposure (including maternal depression), social/academic impairment, cognitive vulnerabilities (rumination, dysfunctional attitudes, and negative cognitive style), and emotional predispositions (negative and positive affect) at baseline. Subsequently, multi-informant diagnostic interviews were completed every 6 months for 2 years.
Results
Self-reported rumination, social/academic impairment, and negative affect best predicted first depression onsets in youth across both samples. Self- and parent-reported depressive symptoms did not consistently predict depression onset after controlling for other predictors. Youth with high scores on the three inventories were approximately twice as likely to experience a future first depressive episode compared to the sample average. Results suggested that one's likelihood of developing depression could be estimated based on subthreshold and threshold risk scores.
Conclusions
Most pediatric depression screening protocols assess current manifestations of depressive symptoms. Screening for prospective first onsets of depressive episodes can be better accomplished via an algorithm incorporating rumination, negative affect, and impairment.
This chapter reviews the developmental epidemiology, and determinants of course and outcome of pediatric depression. Early-onset depression conveys significantly increased risk, compared to later-onset depression for the development of bipolar spectrum disorder. Parents have a right to know the goals and progress of treatment. A high proportion of clinically referred youth with mood disorders have clinically significant suicidal ideation or behavior. Multi-family psychoeducation and family-based attachment therapy show promise in randomized clinical trials. Two selective serotonin reuptake inhibitors, fluoxetine and escitalopram are approved for use in adolescent depression by the Federal Drug Administration (FDA); fluoxetine is also approved for use in preadolescent patients. Patients with co-morbid anxiety or obsessive compulsive disorder (OCD) can usually be treated with the same antidepressant as that used for the depression, although higher dosages may be needed to treat anxiety or OCD.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.